Fotios V. Michelis

Dr. Fotios V. Michelis


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MWMatthew Wieduwilt
Matthew Wieduwilt
LMLeland Metheny
Leland Metheny
MZMei-Jie Zhang
Mei-Jie Zhang
HWHai-Lin Wang
Hai-Lin Wang
NENoel Estrada-Merly
Noel Estrada-Merly
WSWael Saber
Wael Saber
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

11 February 2025 in Blood Advances
Verified
Journal Article
Open access
NDNihar Desai
Nihar Desai
MAMajed Altareb
Majed Altareb
MRMats Remberger
Mats Remberger
CCCarol Chen
Carol Chen
TMTommy Alfaro Moya
Tommy Alfaro Moya
ALArjun Datt Law
Arjun Datt Law
Posttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) transplants remains unclear. We conducted a retrospective study of 413 MSD-HSCT patients receiving peripheral blood stem cell (PBSC) grafts from January 2010 to January 2023. Patients were categorized into 4 groups: group I (calcineurin inhibitor [CNI] + methotrexate [MTX] or mycophenolate mofetil [MMF]), group II (CNI + MTX or MMF + antithymocyte globulin [ATG]), group III (PTCy + ATG + CNI), and group IV (PTCy + CNI + MMF). PTCy was associated with a significant reduction in grade 2- 4 and grade 3-4 acute GVHD and moderate-to-severe chronic GVHD compared with CNI + MTX (or MMF)–containing regimens. PTCy did not increase relapse risk; PTCy reduced nonrelapse mortality, leading to improved GVHD-free/relapse-free survival (GRFS; Hazard Ratio, 0.4; P < .001). PTCy was also associated with improved overall survival. Bloodstream infections were increased with PTCy. The addition of ATG to PTCy did not further improve GRFS and was associated with a higher incidence of clinically significant cytomegalovirus (csCMV) and Epstein-Barr virus (csEBV) reactivation and a numerical increase in NRM. PTCy significantly appeared to improve GRFS in the MSD setting using PBSC grafts. The addition of ATG to PTCy increases csCMV and csEBV reactivation without further improving GRFS. Prospective trials and PTCy dose optimization are warranted.

29 March 2019 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SPShruti Prem
Shruti Prem
EAEshetu G. Atenafu
Eshetu G. Atenafu
ZAZeyad Al‐Shaibani
Zeyad Al‐Shaibani
DLDavid Loach
David Loach
ALArjun Datt Law
Arjun Datt Law
AVAuro Viswabandya
Auro Viswabandya

23 June 2017 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CBChristianne Bourlon
Christianne Bourlon
JLJeffrey H. Lipton
Jeffrey H. Lipton
UDUday Deotare
Uday Deotare
VGVikas Gupta
Vikas Gupta
DKDennis D. Kim
Dennis D. Kim
Fotios V. MichelisFotios V. Michelis
Fotios V. Michelis

29 June 2020 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RARehab Alblooshi
Rehab Alblooshi
SKSolaf Kanfar
Solaf Kanfar
BLBridgette Lord
Bridgette Lord
EAEshetu G. Atenafu
Eshetu G. Atenafu
Fotios V. MichelisFotios V. Michelis
Fotios V. Michelis
JLJeffrey h Lipton
Jeffrey h Lipton

27 October 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
SPShruti Prem
Shruti Prem
SCShiyi Chen
Shiyi Chen
JLJeffrey H. Lipton
Jeffrey H. Lipton
DKDennis D. Kim
Dennis D. Kim
Fotios V. MichelisFotios V. Michelis
Fotios V. Michelis
Cryopreservation of grafts has been established in autologous and cord blood transplantation, yet there is little experience regarding the effect of cryopreservation with sibling and unrelated grafts. We evaluated the effect of cryopreservation of grafts on allogeneic transplant outcomes using related, unrelated and haploidentical donors, including 958 patients, age 18‐74 years (median 55) and using PBSC for various hematologic malignancies. Fresh grafts were received by 648 (68%) patients, 310 (32%) received cryopreserved. There was no difference between fresh vs cryopreserved grafts for neutrophil engraftment (P = .09), platelet engraftment (P = .11), graft failure (5.6% vs 6.8%, P = .46) and grade II‐IV acute graft‐vs‐host disease (GVHD) (P = .71), moderate/severe chronic GVHD was observed in 176 (27%) vs 123 (40%) patients, respectively (P < .001). Multivariable analysis demonstrated no difference between fresh vs cryopreserved for OS (P = .39) and CIR (P = .08) while fresh grafts demonstrated borderline increased NRM (HR 1.27, 95% CI 1.02‐1.59, P = .04). Of note, for patients with no or mild chronic GVHD, CIR was less for fresh compared to cryopreserved (HR = 0.67 for fresh, 95% CI 0.48‐0.92, P = .01). We conclude there were no differences in engraftment and survival between fresh and cryopreserved grafts for allogeneic HCT, thus establishing cryopreservation to be a safe option for allogeneic HCT.